NovaBridge Biosciences (NBP)
NovaBridge Biosciences develops drug candidates for cancer and eye disease, led by givastomig for gastric cancer. It last closed at $0.83 on Nov 20, down 5.66% on the day. Over the last 12 months NBP insiders bought $663K of stock on the open market and sold $154K, according to SEC Form 4 filings.
Key Stats
Last 12 monthsNot reported for this period.
From NBP's SEC filings, latest 20-F/A for the period ending Dec 31, 2025 (filed Jun 16). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Technical AnalysisPrices may be delayed
The stock is 18% below its 20 day and 50% below its 50 day average. It is 138% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 31), near oversold. The nearest support is the Pivot S1 at $0.78, and the nearest resistance the Pivot at $0.88.
| RSI (14) | 30.79 | Weak, oversold below 30 | Neutral |
| MACD | -0.13 | Above its signal line | Bullish |
| Stochastic | 28.2 | Middle of its range | Neutral |
| ADX (14) | 43.3 | Strong downtrend | |
| Williams %R | -75.5 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -51.3 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −8.7% | Change over 10 sessions | Bearish |
| ATR (14) | $0.08 | Typical daily range, 10.1% of price |
| RSI (14) | 27.00 | Oversold below 30 | Oversold |
| MACD | -0.39 | Below its signal line | Bearish |
| Stochastic | 4.8 | Near the bottom of its range | Oversold |
| ADX (14) | 24.2 | Weak trend | |
| Williams %R | -93.8 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -153.3 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −47.8% | Change over 10 sessions | Bearish |
| ATR (14) | $0.26 | Typical daily range, 31.4% of price |
What happened before
See how NBP did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How NBP has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options FlowPrices may be delayed
90DNo whale options trades in NBP in the last 90 days.
NBP Institutional Ownership
Full report →- ●23 buying vs 22 selling
- ▼Held by funds -0.7 pts
- ▼Funds holding -1
- ●Superinvestors: 1 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 48 | 49 | −2.0% |
| In funds' top 10 | 1 | 1 | 0.0% |
| Held by funds | 8.6% | 9.3% | −0.7 pts |
| New / increased | 9 / 14 | 12 / 13 | −8.0% |
| Reduced / sold out | 13 / 9 | 11 / 11 | 0.0% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
NBP Insider Trading
All filings →| Trade date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 18 | Mark Arnold HaglerChief Commercial Officer | Buy | 230,000 | $0.37 | $86K |
| Sep 18 | Phillip Andrew DennisChief Medical Officer | Sale | 8,209 | $0.71 | $6K |
| Sep 9 | Sean Wuxiong CaoChief Bus. Development Officer | Sale | 107,978 | $0.74 | $80K |
| Aug 31 | Cong Claire XuEVP, Clinical Development | Sale | 3,282 | $0.79 | $3K |
| Jul 6 | Cong Claire XuSVP, Clinical Development | Sale | 4,485 | $0.89 | $4K |
| Jun 18 | Phillip Andrew DennisChief Medical Officer | Sale | 8,494 | $0.66 | $6K |
From SEC Form 4 filings by NBP's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper tradingStreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NBP is in one of them and how their past NBP trades turned out.
NBP News Tone and PricePrices may be delayed
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered NBP in an article yet. Here's the latest on the wider market.
About NovaBridge Biosciences
NovaBridge Biosciences is a biotechnology company based in Rockville, Maryland, that develops drug candidates for cancer and eye disease. Its lead program is givastomig, an antibody therapy being tested for gastric cancer and other tumors that express the CLDN18.2 protein. The company is also developing VIS-101, a candidate for wet macular degeneration and diabetic macular edema. Its treatments are aimed at patients worldwide.
- Headquarters
- Rockville, MD

